J&J Seals $5.5bn Deal to End Decade-Long Talc Liability Saga

US healthcare giant Johnson & Johnson (J&J) has struck a landmark agreement to resolve approximately 76,000 lawsuits alleging its talc products caused cancer, aiming to draw a definitive line under a contentious legal battle that has shadowed the conglomerate for a decade.

A $5.5bn Resolution to Eliminate Tail Risk

The company has committed to paying an estimated $5.5 billion, with projections that the total payout could escalate to $7 billion depending on participation levels. This settlement represents a strategic move to remove one of the most significant legal overhangs from the company's balance sheet.

■The landmark deal covers about 76,000 claims, including those consolidated in federal court and related state cases.

■The agreement requires acceptance by 95% of the ovarian cancer claimants to become final.

■J&J leadership maintains the claims are "meritless" but chose to settle to achieve closure and refocus on core pharmaceutical and medical device missions.

Bankruptcy Strategy Failure and Cash Outflow Schedule

Johnson & Johnson previously pursued a controversial "Texas Two Step" strategy, utilizing a shell-company subsidiary to file for bankruptcy three times—a tactic that was ultimately dismissed by courts. The new settlement brings clarity to the financial timeline, though immediate cash relief is not expected.

■The company expects to pay $3 billion in 2027, with further payments scheduled for 2028.

■Unlike previous proposals, this agreement applies only to existing claims, leaving the door open for potential future litigation.

■The accelerated payment schedule—resolving all claims within 18 months rather than over a decade—offers significant liquidity to plaintiffs compared to the failed bankruptcy plans.

From a trading perspective, the removal of legal overhang is a primary catalyst. While the abandoned "Texas Two Step" bankruptcy strategy signaled a failure to cap liabilities via shell companies, this direct settlement clears the deck for 2027. The market will likely absorb the $7bn ceiling as a one-off cost, clearing the path for valuation multiples to recover without the specter of indefinite litigation risk. However, the exclusion of future claims means legal risk premiums for the sector remain elevated.